The 2026 Part D plans became available to the public Oct. 1 at Medicare.gov, and there are serious changes, with Part D ...

Provider directories for Medicare Advantage and AI prior authorization in select states are among the changes in stores for ...

The atrial fibrillation (AF) market across the eight major markets (8MM) is forecast to decline at a negative compound annual ...

Investing.com -- S&P Global Ratings revised its outlook on Bayer AG to negative from stable on Thursday, citing increased risks to growth while affirming the company’s ’BBB’ credit rating. The rating ...

Rankin said the incident was a further example of Brooks manipulating his medical condition to avoid finishing his trial. On ...

Newsroom is open 24 hours, please reach us by email at [email protected] or by phone Monday through Friday 9-5. You can place DBA (Fictitious Business Name Statement) orders online by clicking on t ...

Rivaroxaban for oral suspension, 1 mg/ml (RLD Xarelto) had a market value of roughly $11 million, per IQVIA July 2025 data.

An appeals court decision striking down claims from a patent for a blockbuster drug that rested on language touting its ...

Lupin has introduced Rivaroxaban for Oral Suspension in the US market, offering a generic version of Xarelto. This medication ...

Bayer chief executive Bill Anderson has said that newer product launches have offset the decline in sales of anticoagulant Xarelto in the first quarter, and he is confident that this will continue ...

The product is a generic version of Xarelto for Oral Suspension, 1 mg/mL, originally developed by Janssen Pharmaceuticals, ...

Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) The systematic review included 35 publications on ...